Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.
about
Therapeutic effects of long-circulating miR-135a-containing cationic immunoliposomes against gallbladder carcinoma.Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.Comparison of three different conjugation strategies in the construction of herceptin-bearing paclitaxel-loaded nanoparticles.PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.
P2860
Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Large-scale manufacturing of G ...... a first-in-man clinical trial.
@en
type
label
Large-scale manufacturing of G ...... a first-in-man clinical trial.
@en
prefLabel
Large-scale manufacturing of G ...... a first-in-man clinical trial.
@en
P2093
P1476
Large-scale manufacturing of G ...... a first-in-man clinical trial.
@en
P2093
Christoph Mamot
Christoph Rochlitz
Reto Ritschard
Stefanie Deuster
Uli Loesch
P356
10.1016/J.IJPHARM.2015.02.034
P407
P577
2015-02-18T00:00:00Z